PLOS Neglected Tropical Diseases: A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
![Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times](https://www.globaltimes.cn/Portals/0/attachment/2022/2022-03-14/e4234ce8-5dee-4e2d-b07a-ff0ee8a1853f.jpeg)
Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times
![Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect](https://ars.els-cdn.com/content/image/3-s2.0-B9780323461436000178-f17-03-9780323461436.jpg)
Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect
![DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol](https://www.aihbonline.com/articles/2018/8/3/images/AdvHumBiol_2018_8_3_132_241934_t2.jpg)
DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol
![Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance | PNAS Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance | PNAS](https://www.pnas.org/cms/10.1073/pnas.1717159115/asset/0c701f8c-2341-437d-8b6a-6cc9ecc84a61/assets/graphic/pnas.1717159115fig01.jpeg)
Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance | PNAS
PLOS Neglected Tropical Diseases: A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
![High seroprotection rates achieved with two doses of Sci-B-Vac, a third- generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens - VBI Vaccines High seroprotection rates achieved with two doses of Sci-B-Vac, a third- generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2021/06/VBIV-EASL-2019-Poster_v2.png)
High seroprotection rates achieved with two doses of Sci-B-Vac, a third- generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens - VBI Vaccines
![Vaccines | Free Full-Text | Vector Design for Improved DNA Vaccine Efficacy, Safety and Production | HTML Vaccines | Free Full-Text | Vector Design for Improved DNA Vaccine Efficacy, Safety and Production | HTML](https://www.mdpi.com/vaccines/vaccines-01-00225/article_deploy/html/images/vaccines-01-00225-g002.png)
Vaccines | Free Full-Text | Vector Design for Improved DNA Vaccine Efficacy, Safety and Production | HTML
![Novel vaccine design based on genomics data analysis: A review - Lu - 2021 - Scandinavian Journal of Immunology - Wiley Online Library Novel vaccine design based on genomics data analysis: A review - Lu - 2021 - Scandinavian Journal of Immunology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/182cd067-f080-46c6-a274-2819e1602754/sji12986-fig-0002-m.png)